Study of Safety/Feasibility of a Hybrid Model of Tertiary and Community Delivery of Hepatic Artery Infusion Chemotherapy

The goal of this clinical trial is to help learn about the safety and feasibility of hepatic artery infusion chemotherapy for those who have colorectal liver metastases, both resectable and unresectable, or unresectable intrahepatic cholangiocarcinoma. The main questions it aims to answer are: * safety and feasibility of installing a pump that deliveries chemotherapy to the hepatic artery (the blood vessel that supplies blood to the liver) * help learn more about the safety of patients having pump refills at home or a local clinic versus having it routinely done at the hospital Participants

Trial Details

NCT ID
NCT07201519
Phase
PHASE2
Sponsor
Michael J Cavnar, MD
Status
RECRUITING
Cancer Type
Colorectal Cancer
Interventions
  • Hepatic Artery Infusion Pump (HAIP)
  • Standard Treatment
  • Community Treatment
  • Systemic Chemotherapy Standard of Care
  • Standard Of Care targeting driver mutations
Locations (sample)
  • Lexington, Kentucky, United States|37.98869,-84.47772

Key Eligibility Criteria

  • Colorectal adenocarcinoma metastatic to the liver which is either Unresectable (group A) or Resectable (group B; ie, will be completely resected), …
  • Histologically confirmed unresectable intrahepatic cholangiocarcinoma (group C), with presence of less than 70% liver involvement with no definitiv…
  • Patients \> or equal 18 years of age
  • ECOG Performance Status of 0 - 1 (APPENDIX C)

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colorectal Cancer Trials on Trialify →